This inventor holds 4 USPTO granted patents. Top assignee: Tularik Limited. Active years: 2001-2002.
Company Filing History:
Years Active: 2001-2002
Title: Catherine Régnier: Innovator in Biopharmaceuticals
Introduction
Catherine Régnier is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biopharmaceuticals, holding a total of 4 patents. Her work focuses on IκB kinase, specifically the IKK-α proteins and related nucleic acids.
Latest Patents
Catherine's latest patents include innovative methods and compositions related to IκB kinase, IKK-α. These inventions provide methods for producing polypeptides recombinantly from transformed host cells using IKK-α encoding nucleic acids. Additionally, her patents include isolated IKK-α hybridization probes and primers that can specifically hybridize with IKK-α genes. The inventions also encompass IKK-α-specific binding agents, such as specific antibodies, and methods for utilizing these compositions in diagnosis, therapy, and the biopharmaceutical industry.
Career Highlights
Catherine has established herself as a key figure in her field through her work at Tularik Limited. Her innovative research has paved the way for advancements in therapeutic applications and biopharmaceutical development.
Collaborations
Catherine has collaborated with notable colleagues, including Mike Rothe and Zhaodan Cao, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Catherine Régnier's contributions to the field of biopharmaceuticals through her patents and collaborative efforts highlight her role as a leading inventor. Her work continues to impact the industry positively, paving the way for future advancements.